Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06588868
Recruiting Observational

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Italiana Linfomi - ETS
Phase
Observational
Started
2025-02-27
Last updated
2025-12-02

Condition(s) studied

Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-Cell Lymphoma/Sezary Syndrome

Study summary

The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria1. * Age ≥18 years. * Have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2023. * Availability of complete medical records in order to provide protocol required variables * Signed written informed consent. Exclusion Criteria: * Patients not meeting the above-mentioned inclusion criteria. * Refuse to sign a written informed consent.

Primary outcome measure(s)

  • To evaluate the different systemic treatment approaches in real life settings in patients with CTCL. — The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)
    Type of systemic therapies used in real-life settings for the treatment of CTCL according to disease stage.
  • To evaluate the different systemic treatment approaches in real life settings in patients with CTCL. — The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)
    Frequency of systemic therapies used in real-life settings for the treatment of CTCL according to disease stage.
  • To evaluate the different systemic treatment approaches in real life settings in patients with CTCL. — The endpoint will be evaluated from the beginning to the end of the study (up to 18 months)
    Evaluation of which systemic therapies are used as first-line compared to which are used as further lines of treatment

Trial sites (18)

FacilityCityRegionStatus
AOU Ospedali Riuniti delle Marche - Clinica di Ematologia Ancona Italy Recruiting
IRCCS Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia Bari Italy Recruiting
U.O.C. Dermatologia e Venereologia Universitaria - A.O.U. Policlinico Consorziale Bari Italy Not Yet Recruiting
Policlinico S.Orsola-Malpighi - Istituto di Ematologia Bologna Italy Recruiting
ASST Spedali Civili di Brescia - S.C. Ematologia Brescia Italy Not Yet Recruiting
A.O. Brotzu Ospedale Businco - S.C. Ematologia e CTMO Cagliari Italy Not Yet Recruiting
A.O.U. Policlinico S. Marco - U.O.C. di Ematologia Catania Italy Not Yet Recruiting
Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi Florence Italy Recruiting
S.C. Dermatologia - E.O. Galliera Genova Italy Recruiting
Oncoematologia - ASST Fatebenefratelli - Sacco Milan Italy Not Yet Recruiting
U.O.C. Dermatologia - Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda Milan Italy Recruiting
U.O.C. Clinica Dermatologica - A.O.U. di Padova Padova Italy Not Yet Recruiting
U.O.C Ematologia 1 - IRCCS Fondazione Policlinico San Matteo Pavia Italy Not Yet Recruiting
IRCCS I.F.O. San Gallicano - UOSD Porfirie e Malattie Rare Roma Italy Recruiting
Skin Cancer Center - IRCCS Istituto Dermopatico dell'Immacolata Roma Italy Not Yet Recruiting
U.O.C. Dermatologia - A.O.U. Senese Siena Italy Not Yet Recruiting
A.O.U. Città della Salute e della Scienza di Torino - S.C. Dermatologia U Torino Italy Recruiting
A.O.U.I. di Verona - U.O.C. Ematologia Verona Italy Recruiting

More Fondazione Italiana Linfomi - ETS trials in Italy

Primary Cardiac Lymphoma: Italian Multicenter Experience Recruiting
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy Recruiting
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. Active, not recruiting
Long-term Assessment of Chlormethine Gel in Mycosis Fungoides Starting soon
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients Active, not recruiting

Other trials for the same condition

Long-term Assessment of Chlormethine Gel in Mycosis Fungoides Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06588868 on ClinicalTrials.gov ↗ ← All trials in Italy